




Hepatitis

Industry Perspective



By: Hetero Labs Limited Shailesh Pednekar



Current Trends

Demand And Uptake In LMICs







Demand and Uptake In LMICs

High APAC / CIS/Egypt

- CIS Kyrghystan, Uzbekistan
- APAC Myanmar, Vietnam , Indonesia, Mongolia, India
- Egypt / Pakistan / Bangladesh / Algeria / Morocco

Differentiating Factors

In-country Healthcare Systems : Better In Asia And CIS Compared To Africa

Availability Of Diagnostic Tools : In Africa Diagnostic Tools Are Not Widely Available And Accessible
 Affordability : More Patients Getting Treated In Private Setup In Asia And CIS Compared To Africa
 Awareness : Greater Amongst Patients And Healthcare Professionals In High Uptake Countries
 Number Of Injection Drug Users: Major Transmission Route (Vs HIV/HEP Co Infection Limited)
 Fund Allocation And National Level Programs: NVHP (National Viral Hepatitis Program)
 Hep B Vs C : Relatively High Hepatitis B Prevalence Globally, Africa More Sensitized Towards Hep B

Low LMIC's

- Africa in General
- Other LDC's



Challenges Under Current Settings







Challenges

Quality

- Exhaustive And Expensive SRA Or WHO PQ Prequalification Approvals. Vs
- Non Licensed And Regional Players Who Are Faster To The Market.
- Country Level Regulatory Requirements
- Quality Of Non Licensed / Regional Players And There Prices. Given That IP Landscape For API's Is Still Loose.

Competition

- □ With In Licensed Players :
 - Investment In BE And Other SRA Approvals
 - Price Aggressiveness Due Limited Opportunities Currently.
- Generics : Non Licensed And Regional Players

? Given This Situation How Much Investment Will Be Affordable And By How Many.



Finding Patient Population

□ Superior DAAs Vs. Interferons

□ Success Countries :

- Products Registered By Multiple Companies
- Supplies Initiated
- Availability Of Oral Therapy With DAAs
 For Existing Patients –Treated And Cured

□ Non-success Countries :

- Hep C Is Not On A High Agenda.
- Few Countries Have Taken Baby Steps
- Other Countries Still Evaluating.
- Funding Is A Big Challenge Currently.
- Limited Diagnostic Services.
- Difficult To Find Asymptomatic Patient Population

Medical Specialists :

□ Gastroenterologists/ Hepatologists Limiting Access.

□ In General Id Doctors Not Treating Hep C In Africa.

Working With Injection Drug Users

- □ <u>Source Of Infection</u> need For Regular Monitoring
- Working with IDU population is a challenge needs a robust social support systems.
- Required Investment and Infrastructure Chances Of Relapse



Scaling Up

Hepatitis Treatment





Steps for Scale up

Service Bundling : One Point Solution

- Tie Up With Diagnostic Facilities And Treatment Providers
- Offering Complete Test And Treat Package

Bringing Hepatitis To The Level Of HIV/TB/MALARIA

- Funding
- Innovative Financing
- Soft Loans

General Practitioners Treating Hepatitis

- Involving GPs For Increased Accessibility And Affordability
- Possible With Simplified Treatment Regimen With DAAs

Need For National Level Programs (Eg.Sucess Countries)

- <u>Ethiopia</u> : Patient Pooling----quantification For PFSA Tender
- <u>Cameroon</u> : Procurement Of Hepatitis Commodities Via CENAME Tender
- <u>Rwanda</u>: started a pilot program with innovator products
- Indonesia : Allocated Budget For Hepatitis Program----MOH Tender Procurement











Steps for Scale up

Socio-Economic Impact

• Benefit To Countries For Treating Hepatitis Patients

Hepatitis In Primary Healthcare

- Need more screening for Hepatitis B And C
- Improving Availability Of Other Diagnostic Tools

Turnkey Projects For Countries

- Facilitate Treatment Programs
- Countries To Take Over After Witnessing The Success

Collective Efforts

- NGOs and World Hepatitis Alliance
- MOH
- Funding Bodies
- Manufacturers











Thank You!

